Lidocaine vs pirmenol
Ventricular fibrillation · patients with myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
3,747 questions · 3,943 findings · 594 reviews
No studies found 784 · 19.9%GRADE not reported 530 · 13.4%Very low 1,040 · 26.4%Low 981 · 24.9%Moderate 444 · 11.3%High 164 · 4.2%
Pharmacological agents vs placebo
Cognitive performance on psychometric tests · Participants with chronic cognitive impairment in traumatic brain injury
1 finding from 1 review
- Pharmacotherapy for chronic cognitive impairment in traumatic brain injury 2015 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 274 participantsVery low
MET plus any intervention vs other therapies plus that intervention
Pain A 0 t o 100 visual or numerical scale, where 0 equals no pain at all and 100 is the worst pain imaginable · patients with non‐specific low‐back pain (LBP)
1 finding from 1 review
- no estimate extracted7 studies · 232 participantsLow
MET vs all other therapies
Pain A 0 t o 100 visual or numerical scale, where 0 equals no pain at all and 100 is the worst pain imaginable · patients with non‐specific low‐back pain (LBP)
1 finding from 1 review
- no estimate extracted2 studies · 88 participantsVery low
Gabapentin vs carbamazepine
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · intensive care unit in India
1 finding from 1 review
- Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes onlyno estimate extracted24 participantsVery low
Gabapentin vs carbamazepine
Sedation score (numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless, 6 = asleep, no response) · intensive care unit in India
1 finding from 1 review
- Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes onlyno estimate extracted24 participantsVery low
Gabapentin vs placebo
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients with pain in Guillain‐Barré syndrome
It is very uncertain whether gabapentin changes pain score (numerical rating scale of 0 to 10: 0 = no pain, 10 =… compared with placebo (very low certainty).
1 finding from 1 review
- Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 54 participantsVery low
Gabapentin vs placebo
Sedation score (numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless, 6 = asleep, no response) · patients with pain in Guillain‐Barré syndrome
It is very uncertain whether gabapentin changes sedation score (numerical rating scale of 1 to 6: 0 = anxious,… compared with placebo (very low certainty).
1 finding from 1 review
- Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 54 participantsVery low
Carbamazepine vs placebo
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients with pain in Guillain‐Barré syndrome
1 finding from 1 review
- Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes onlyno estimate extracted1 study · 24 participantsVery low
Carbamazepine vs placebo
Sedation score (numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless, 6 = asleep, no response) · patients with pain in Guillain‐Barré syndrome
1 finding from 1 review
- Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes onlyno estimate extracted1 study · 24 participantsVery low
Tinzaparin vs placebo
Pain intensityNumeric pain scale · people with sickle cell disease
1 finding from 1 review
- Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes onlyno estimate extracted1 study · 253 participantsVery low
Dalteparin vs placebo
Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire either generic or SCD specific) ‐ not measured · sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
- Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Dalteparin vs placebo
Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific) ‐ not measured · sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
- Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Tinzaparin vs placebo
Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire either generic or SCD specific) ‐ not measured · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
- Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Tinzaparin vs placebo
Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific) ‐ not measured · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
- Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Bovine lung lavage surfactant extract vs porcine minced lung surfactant extract
Severe intraventricular hemorrhage in infants who received neuroimaging · Preterm infants for treatment of RDS
It is very uncertain whether bovine lung lavage surfactant extract changes severe intraventricular hemorrhage in infants who received… compared with porcine minced lung surfactant extract (very low certainty).
1 finding from 1 review
- Comparison of animal‐derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm… 2015 · Cochrane Headline outcomes onlyRR 0.83 [0.29, 2.41]1 study · 54 participantsVery low
Modified bovine minced lung surfactant extract vs porcine minced lung surfactant extract
Severe intraventricular hemorrhage in infants who received neuroimaging · Preterm infants for treatment of RDS
It is very uncertain whether modified bovine minced lung surfactant extract changes severe intraventricular hemorrhage in infants who received… compared with porcine minced lung surfactant extract (very low certainty).
1 finding from 1 review
- Comparison of animal‐derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm… 2015 · Cochrane Headline outcomes onlyRR 1.28 [0.83, 1.97]7 studies · 705 participantsVery low
Modified bovine minced lung surfactant extract vs porcine lung lavage surfactant
Severe intraventricular hemorrhage in infants who received neuroimaging · Preterm infants for treatment of RDS
The review found no eligible studies for this question.
1 finding from 1 review
- Comparison of animal‐derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm… 2015 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Pyridoxal 5 phosphate (vitamin B6) vs placebo
General mental state: Positive psychiatric symptom score PANSS5. Scale from: 7 to 49. · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
- Pyridoxal 5 phosphate for neuroleptic‐induced tardive dyskinesia 2015 · Cochrane Headline outcomes onlyno estimate extracted1 study · 15 participantsLow
Pyridoxal 5 phosphate (vitamin B6) vs placebo
General mental state: Negative psychiatric symptoms PANSS5. Scale from: 7 to 49. · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
- Pyridoxal 5 phosphate for neuroleptic‐induced tardive dyskinesia 2015 · Cochrane Headline outcomes onlyno estimate extracted1 study · 15 participantsLow